Showing 1931-1940 of 2314 results for "".
- Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoints-in-dry-eye-disease-chamber-crossover-clinical-trial/2480957/Aldeyra Therapeutics announced the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was st
- Novartis Acquires Kedalion Therapeutics and its Ocular Delivery Platformhttps://modernod.com/news/novartis-acquires-kedalion-therapeutics-and-its-ocular-delivery-platform/2480952/Novartis announced that it has acquired Kedalion Therapeutics and its AcuStream technology, a device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.1,2 Terms of the deal were
- Kubota Vision Announces End-of-Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Diseasehttps://modernod.com/news/kubota-vision-announced-end-of-phase-3-clinical-trial-of-emixustat-in-patients-with-stargardt-disease/2480932/Kubota Vision announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (emixustat) in patients with macular atrophy secondary to Stargardt disease. The study was a multicenter, randomized, double-masked, and placebo-controlled phase 3 clini
- LumiThera Presents New Data from LIGHTSITE III Trial Showing Improvement in Vision in Intermediate Dry AMDhttps://modernod.com/news/lumithera-presents-new-data-from-lightsite-iii-trial-showing-improvement-in-vision-in-intermediate-dry-amd/2480930/LumiThera announced detailed findings in its LIGHTSITE III, multicenter clinical trial in non-neovascular age-related macular degeneration (AMD) subjects treated with photobiomodulation (PBM) using the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked,
- Nanodropper Announces Growth in Partnerships and Availabilityhttps://modernod.com/news/nanodropper-announces-increases-in-partnerships-and-availability/2480921/Nanodropper, a volume-reducing adaptor for eye drop bottles, announced major growth over the last 12 months, including an 832% increase in clinic partnerships, expanding to more than 840 clinic locations since June of 2021. Nanodropper has also more than doubled its team as it finalized rese
- Eyenovia Announces Planned Chief Executive Officer Transitionhttps://modernod.com/news/eyenovia-announces-planned-chief-executive-officer-transition/2480898/Eyenovia announced that Sean Ianchulev, MD, co-founder, chief medical officer, and chief executive officer, will step down as chief executive officer and transition to the role of non-executive Chairman of the Board. The definitive timeline for the transition will be determin
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi
- Oertli Expands its Direct Distribution Networkhttps://modernod.com/news/oertli-expands-its-direct-distribution-network/2480889/Oertli Instrumente acquired the Swiss distributor Domedics AG and integrated the company as of June 1 into their global brand. Terms of the deal were not disclosed. In September 2021, Oertli Instrumente took over the majority of shares in Domedics, a Switzerland-base
- Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-completion-of-enrollment-in-phase-3-tranquility-2-trial-in-patients-with-dry-eye-disease/2480746/Aldeyra Therapeutics announced completion of enrollment in the phase 3 TRANQUILITY-2 trial of 0.25% reproxalap ophthalmic solution in patients with dry eye disease. The multicenter, double-masked, parallel-group TRANQUILITY-2 trial enrolled 361 patients randomized to receive either
- FDA Approves Staar Surgical's EVO Visian Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-announces-fda-approval-of-evo-visian-implantable-collamer-lenses/2480724/Staar Surgical Company announced that the FDA has granted approval of the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the correction of myopia and myopia with astigmatism. "Following FDA approval, prospective patients in the U.S. and their doctors may n